

RD  
AKIMA-DTSV 23 MAR 2005.**PATENT****UNITED STATES PATENT AND TRADEMARK OFFICE**  
(Case No. MBHB02,742-F (400/131))

IN THE APPLICATION OF:

McSwiggen, et al.	)	Examiner:	To Be Assigned
Serial 10/665,951	)	Group Art Unit:	1635
No.	)		
Filed: September 18, 2003	)	Confirmation No.:	8325
Title RNA Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)	)	Fax No.:	(703) 746-9195


**TRANSMITTAL LETTER**

Mail Stop OIPE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Attn: Office of Initial Patent Examination's  
 Filing Receipt Corrections

Dear Sir:

1. In regard to the above identified application,  
 We are transmitting herewith the attached:  
  - a) Request for Corrected Filing Receipt
  - b) Copy of Filing Receipt with changes noted thereon
2. With respect to fees:  
  - a) It is believed no fee is due at this time.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 (Fax No. (703) 746-9195) on March 22, 2005.

Respectfully submitted,  
 McDonnell Boehnen Hulbert & Berghoff LLP  
  
 By: Anita J. Terpstra, Ph.D.  
 Registration No. 47,132

Date: March 22, 2005

**PATENT**

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
(Case No. MBHB02,742-F (400/131))

IN THE APPLICATION OF: )  
McSwiggen, et al. )  
Serial No. 10/665,951 ) Examiner: To Be Assigned  
Filed: September 18, 2003 ) Group Art Unit: 1635  
Title RNA Interference Mediated Inhibition Of ) Confirmation No.: 8325  
Vascular Endothelial Growth Factor And )  
Vascular Endothelial Growth Factor )  
Receptor Gene Expression Using Short )  
Interfering Nucleic Acid (siNA) )

**REQUEST FOR CORRECTED FILING RECEIPT**

Mail Stop OIPE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Attention: Office of Initial Patent Examination's  
Filing Receipts Corrections**

1. Attached is a copy of a corrected filing receipt received from the PTO in the above-referenced application for which issuance of a new corrected filing receipt is respectfully requested.
  
  2. There is an error with respect to the following date, which is incorrectly entered.

### Error in

**Domestic Priority data as claimed by applicant**

This application is a CIP of 10/664,767 09/16/2003 ABN

which is a CIP of PCT/US03/05022 02/20/2003

which claims benefit of 60/358 580 02/20/2002

and claims benefit of 60/363,124 03/11/2002

and claims benefit of 60/386,782 06/06/2002

International Journal of Bifurcation and Chaos 2013.03:1.

8/22/2006 4:12:37 PM [Eastern Standard Time]

APPLICATION NO. 10/665,951  
ATTORNEY DOCKET NO. MBILB02-742-F (400/131)

and claims benefit of 60/393, 796 07/03/2002  
and claims benefit of 60/399,348 07/29/2002  
and claims benefit of 60/406,784 08/29/2002  
and claims benefit of 60/408,378 09/05/2002  
and claims benefit of 60/409,293 09/09/2002  
and claims benefit of 60/440,129 01/15/2003  
and is a CIP of 10/306,747 11/27/2002  
which claims benefit of 60/334,461 11/30/2001  
and said PCT/US03/05022 02/20/2003  
is a CIP of 10/287,949 11/04/2002

### **Correct Data**

Domestic Priority data as claimed by applicant:

This application is a CIP of 10/664,767 09/16/2003  
which is a CIP of PCT/US03/05022 02/20/2003  
which claims benefit of 60/358,580 02/20/2002  
and claims benefit of 60/363,124 03/11/2002  
and claims benefit of 60/386,782 06/06/2002  
and claims benefit of 60/393, 796 07/03/2002  
and claims benefit of 60/399,348 07/29/2002  
and claims benefit of 60/406,784 08/29/2002  
and claims benefit of 60/408,378 09/05/2002  
and claims benefit of 60/409,293 09/09/2002  
and claims benefit of 60/440,129 01/15/2003  
and said PCT/US03/05022 02/20/2003  
is a CIP of 10/306,747 11/27/2002  
which claims benefit of 60/334,461 11/30/2001  
and said PCT/US03/05022 02/20/2003  
is a CIP of 10/287,949 11/04/2002

APPLICATION NO. 10/665,951  
ATTORNEY DOCKET NO. MBHB02-742-F (400/131)

and a CIP of PCT/US02/17674 05/29/02

3. Applicant believes that no fee is due in connection with this filing, however, if a fee is due, the Commissioner is authorized to charge our deposit account number 13-1249.

Respectfully submitted,  
McDonnell, Boehnen, Hulbert & Berghoff LLP

Date: March 22, 2005

By:   
Anita J. Terpstra, Ph.D.  
Registration No. 47,132



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (E) DATE	ART UNIT	FIL FEE RECD	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/665,951	09/18/2003	1635	626	MBHB02-742-F (400.131)	19	36	4

## CONFIRMATION NO. 8325

020306  
 McDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
 300 S. WACKER DRIVE  
 32ND FLOOR  
 CHICAGO, IL 60606

## CORRECTED FILING RECEIPT



"OC000000015419979"

Date Mailed: 03/10/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

James McSwiggen, Boulder, CO;  
 Leonid Beigelman, Longmont, CO;  
 Pamela Pavco, Lafayette, CO;

## DOCKETED

MAR 15 2005

DUE DATE: RECEIVED  
BY: RECEIVED

## Assignment For Published Patent Application

Sima Therapeutics, Inc., Boulder, CO

Power of Attorney: The patent practitioners associated with Customer Number 020306.

## Domestic Priority data as claimed by applicant

This application is a CIP of 10/664,767 09/16/2003 ABN, which is a CIP of PCT/US03/05022 02/20/2003 which claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/393,796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and is a CIP of 10/306,747 11/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002

This application is a CIP of 10/664,767 09/16/2003 which is a CIP of PCT/US03/05022 02/20/2003 which claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/393,796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and said PCT/US03/05022 02/20/2003 is a CIP of 10/306,747 11/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002 and a CIP of PCT/US02/17674 05/29/02

**Foreign Applications****If Required, Foreign Filing License Granted: 12/12/2003****The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/665,951****Projected Publication Date:** Not Applicable**Non-Publication Request:** No**Early Publication Request:** No**\*\* SMALL ENTITY \*\*****Title**

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING

LICENSE GRANTED\* DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).